Yang LIU, Siyu LI, Zhigang ZHANG, Zhanjun LV, Huijie JIANG, Xiao TAN2, Fengquan LIU

Effects of valproic acid on sympathetic activity and left ventricularmyocardial remodelling in rats during pressure overload

Background/aim: Pressure overload induces cardiac remodelling and results in heart failure. Enhanced sympathetic outflow participates in the development of cardiac remodelling for the duration of pressure overload as an independent factor. Valproic acid has recently been shown to reduce neuronal injury and have antiinflammatory and antiapoptotic effects as a histone deacetylase inhibitor. We speculate that the drug plays a specific role in alleviating cardiac remodelling by inhibiting sympathetic activity. Materials and methods: Surgery of partial abdominal aortic constriction was performed on male Sprague-Dawley rats. After 4 weeks, animal models of pressure overload were validated and then valproic acid (300 mg/kg) was administrated to rats once a day for the next 4 weeks. Experimental parameters were detected 4 weeks after validation. Results: The administration of valproic acid alleviated cardiomyocyte hypertrophy, myocardial interstitial fibrosis and left ventricular diastolic dysfunction caused by partial abdominal aortic constriction. Valproic acid reduced the levels of plasma and local norepinephrine, augmented concentrations of hypothalamic gamma-aminobutyric acid, and had no side effects on the hepatic and renal function of the animals. Conclusion: These results suggest that valproic acid may be a safe and effective therapeutic strategy for the inhibition of sympathetic outflow and cardiac remodelling.

PDF

___

1. Givvimani S, Kundu S, Narayanan N, Armaghan F, Qipshidze N, Pushpakumar S, Vacek TP, Tyagi SC. TIMP-2 mutant decreases MMP-2 activity and augments pressure overload induced LV dysfunction and heart failure. Arch Physiol Biochem 2013; 119: 65-74.
2. Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999; 34: 724-728.
3. Dab H, Hachani R, Hodroj W, Sakly M, Bricca G, Kacem K. Differential control of collagen synthesis by the sympathetic and reninangiotensin systems in the rat left ventricle. Auton Neurosci 2009; 151: 106-110.
4. Lee JH, Kim K, Jo YH, Lee SH, Kang C, Kim J, Park CJ, Kim MA, Lee MJ, Rhee JE. Effect of valproic acid on survival and neurologic outcomes in an asphyxial cardiac arrest model of rats. Resuscitation 2013; 84: 1443-1449.
5. Jin HB, Guo XM. Valproic acid ameliorates coxsackievirus-B3- induced viral myocarditis by modulating Th17/Treg imbalance. Virol J 2016; 13: 168.
6. Andreou AP, Shields KG, Goadsby PJ. GABA and valproate modulate trigeminovascular nociceptive transmission in the thalamus. Neurobiol Dis 2010; 37: 314-323.
7. Takebayashi M, Motohashi N, Saito H, Kagaya A, Yamawaki S. Effect of acute treatment with sodium valproate on catecholamine and serotonin synthesis in mouse cerebral cortex. Neuropsychobiology 1995; 32: 124-127.
8. Breum L, Astrup A, Gram L, Andersen T, Stokholm KH, Christensen NJ, Werdelin L, Madsen J. Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. Metabolism 1992; 41: 666-670.
9. Tibiriçà E, Catelli M, Lessa MA, Roegel JC, Feldman J, Monassier L, Bousquet P. Inhibition of the centrally induced increases in myocardial oxygen demand in rabbits by chronic treatment with baclofen, a selective GABAB agonist. Br J Pharmacol 1995; 115: 1331-1335.
10. Jiang N, Shi P, Li HW, Lu S, Braseth L, Cuadra AE, Raizada MK, Sumners C. Phosphate-activated glutaminase-containing neurons in rat paraventricular nucleus express angiotensin type 1 receptors. Hypertension 2009; 54: 845-851.
11. Badoer E. Role of the hypothalamic PVN in the regulation of renal sympathetic nerve activity and blood flow during hyperthermia and in heart failure. Am J Physiol Renal Physiol 2010; 298: F839-F846.
12. Yang Z, Coote JH. Influence of the hypothalamic paraventricular nucleus on cardiovascular neurones in the rostral ventrolateral medulla of the rat. J Physiol 1998; 513: 521-530.
13. Blair ML, Piekut D, Want A, Olschowka JA. Role of the hypothalamic paraventricular nucleus in cardiovascular regulation. Clin Exp Pharmacol Physiol 1996; 23: 161-165.
14. Vaz GC, Bahia AP, de Figueiredo Müller-Ribeiro FC, Xavier CH, Patel KP, Santos RA, Moreira FA, Frézard F, Fontes MA. Cardiovascular and behavioral effects produced by administration of liposome-entrapped GABA into the rat central nervous system. Neuroscience 2015; 285: 60-69.
15. Kim HJ, Rowe M, Ren M, Hong JS, Chen PS, Chuang DM. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther 2007; 321: 892-901.
16. Kabakus N, Ay I, Aysun S, Söylemezoglu F, Özcan A, Celasun B. Protective effects of valproic acid against hypoxic-ischemic brain injury neonatal rats. J Child Neurol 2005; 20: 582-587.
17. Ren M, Leng Y, Jeong M, Leeds PR, Chuang DM. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J Neurochem 2004; 89: 1358-1367.
18. Wang ZF, Leng Y, Tsai LK, Leeds P, Chuang DM. Valproic acid attenuates blood-brain barrier disruption in a rat model of transient focal cerebral ischemia: the roles of HDAC and MMP-9 inhibition. J Cereb Blood Flow Metab 2011; 31: 52-57.
19. Balakumar P, Singh M. The possible role of caspase-3 in pathological and physiological cardiac hypertrophy in rats. Basic Clin Pharmacol Toxicol 2006; 99: 418-424.
20. Shimoyama M, Hayashi D, Takimoto E, Zou YZ, Oka T, Uozumi H, Kudoh S, Shibasaki F, Yazaki Y, Nagai R et al. Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy. Circulation 1999; 100: 2449-2454.
21. Obayashi M, Yano M, Kohno M, Kobayashi S, Tanigawa T, Hironaka K, Ryouke T, Matsuzaki M. Dose-dependent effect of ANG II-receptor antagonist on myocyte remodeling in rat cardiac hypertrophy. Am J Physiol 1997; 273: H1824-H1831.
22. Briest W, Hölzl A, Raßler B, Deten A, Leicht M, Baba HA, Zimmer HZ. Cardiac remodeling after long term norepinephrine treatment in rats. Cardiovasc Res 2001; 52: 265-273.
23. Perlini S, Palladini G, Ferrero I, Tozzi R, Fallarini S, Facoetti A, Nano R, Clari F, Busca G, Fogari R et al. Sympathectomy or doxazosin, but not propranolol, blunt myocardial interstitial fibrosis in pressure-overload hypertrophy. Hypertension 2005; 46: 1213-1218.
24. Allen AM. Inhibition of the hypothalamic paraventricular nucleus in spontaneously hypertensive rats dramatically reduces sympathetic vasomotor tone. Hypertension 2002; 39: 275-280.
25. Ito S, Komatsu K, Tsukamoto K, Kanmatsuse K, Sved AF. Ventrolateral medulla AT1 receptors support blood pressure in hypertensive rats. Hypertension 2002; 40: 552-559.
26. Esler M, Kaye D. Sympathetic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease. J Cardiovasc Pharmacol 2000; 35: S1-S7.
27. Zhang K, Li YF, Patel KP. Reduced endogenous GABAmediated inhibition in the PVN on renal nerve discharge in rats with heart failure. Am J Physiol Regul Integr Comp Physiol 2002; 282: R1006-R1015.
28. Hardy SGP. Hypothalamic projections to cardiovascular centers of the medulla. Brain Res 2001; 894: 233-240.
29. Pyner S, Coote JH. Identification of branching paraventricular neurons of the hypothalamus that project to the rostroventrolateral medulla and spinal cord. Neuroscience 2000; 100: 549-556.
30. Dampney RAL. Functional organization of central pathways regulating the cardiovascular system. Physiol Rev 1994; 74: 323-364.
31. Swanson LW, Sawchenko PE. Hypothalamic integration: organization of the paraventricular and supraoptic nuclei. Annu Rev Neurosci 1983; 6: 269-324.
32. Takeda K, Buñag RD. Augmented sympathetic nerve activity and pressor responsiveness in DOCA hypertensive rats. Hypertension 1980; 2: 97-101.
33. Takeda K, Nakata T, Takesako T, Itoh H, Hirata M, Kawasaki, S, Hayashi J, Oguro M, Sasaki S, Nakagawa M. Sympathetic inhibition and attenuation of spontaneous hypertension by PVN lesions in rats. Brain Res 1991; 543: 296-300.
34. Takenaka K, Sasaki S, Uchida A, Fujita H, Nakamura K, Ichida T, Itoh H, Nakata T, Takeda K, Nakagawa M. GABABergic stimulation in hypothalamic pressor area induces larger sympathetic and cardiovascular depression in spontaneously hypertensive rats. Am J Hypertens 1996; 9: 964-972.
35. Park JB, Jo JY, Zheng H, Patel KP, Stern JE. Regulation of tonic GABA inhibitory function, presympathetic neuronal activity and sympathetic outflow from the paraventricular nucleus by astroglial GABA transporters. J Physiol 2009; 587: 4645-4660.
36. Johannessen CU. Mechanisms of action of valproate: a commentatory. Neurochem Int 2000; 37: 103-110.
37. Löscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2002; 16: 669-694.
38. Owens MJ, Nemeroff CB. Pharmacology of valproate. Psychopharmacol Bull 2003; 37: 17-24.
39. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002; 16: 695-714.
40. Rosenberg G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell Mol Life Sci 2007; 64: 2090-2103.
41. Terbach N, Williams RSB. Structurefunction studies for the panacea, valproic acid. Biochem Soc Trans 2009; 37: 1126- 1132.
42. Cunningham MO, Woodhall GL, Jones RSG. Valproate modifies spontaneous excitation and inhibition at cortical synapses in vitro. Neuropharmacology 2003; 45: 907-917.
43. Palmer JE, Chronicle EP, Rolan P, Mulleners WM. Cortical hyperexcitability is cortical under-inhibition: evidence from a novel functional test of migraine patients. Cephalalgia 2000; 20: 525-532.
44. Kee HJ, Sohn IS, Nam KI, Park JE, Qian YR, Yin Z, Ahn Y, Jeong MH, Bang YJ, Kim N et al. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 2006; 113: 51-59.
45. Kang SH, Seok YM, Song MJ, Lee HA, Kurz T, Kim I. Histone deacetylase inhibition attenuates cardiac hypertrophy and fibrosis through acetylation of mineralocorticoid receptor in spontaneously hypertensive rats. Mol Pharmacol 2015; 87: 782-791.